Repligen | RGEN - Operating Profit


Repligen reported $21.13M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agilent USD 444M 45M Jun/2026
Align Technology USD 191.32M 13.27M Jun/2026
Bio Techne USD 75.49M 21.03M Mar/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Bruker USD 69.6M 59.4M Jun/2026
Charles River Laboratories USD 119.89M 9K Jun/2026
Danaher USD 1.13B 217M Jun/2026
Dentsply International USD 84M 52M Jun/2026
General Electric Aerospace USD 2.32B 549M Mar/2026
Henry Schein USD 200M 18M Jun/2026
Illumina USD 260M 21M Jun/2026
IQVIA Holdings USD 2.6B 2.03B Jun/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Repligen USD 21.13M 1.15M Jun/2026
Revvity USD 126.14M 43.36M Jun/2026
Standard Biotools USD -9.42M 12.51M Mar/2026
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
Waters USD -86M 234M Jun/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026